About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Breast Cancer Liquid Biopsy Market Size, Share | Growth Report 2031

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Product and Service (Reagent Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA), By Applications (Diagnostics, Prognostics, Risk assessment ) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54110DR
Author : Straits Research

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Breast Cancer Liquid Biopsy Market Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    1. Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    5. U.S.
      1. By Product and Service
        1. Introduction
          1. Product and Service By Value
        2. Reagent Kits
          1. By Value
        3. Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Diagnostics
          1. By Value
        3. Prognostics
          1. By Value
        4. Risk assessment 
          1. By Value
    6. Canada
    1. Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    5. U.K.
      1. By Product and Service
        1. Introduction
          1. Product and Service By Value
        2. Reagent Kits
          1. By Value
        3. Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Diagnostics
          1. By Value
        3. Prognostics
          1. By Value
        4. Risk assessment 
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    5. China
      1. By Product and Service
        1. Introduction
          1. Product and Service By Value
        2. Reagent Kits
          1. By Value
        3. Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Diagnostics
          1. By Value
        3. Prognostics
          1. By Value
        4. Risk assessment 
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    5. UAE
      1. By Product and Service
        1. Introduction
          1. Product and Service By Value
        2. Reagent Kits
          1. By Value
        3. Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Diagnostics
          1. By Value
        3. Prognostics
          1. By Value
        4. Risk assessment 
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product and Service
      1. Introduction
        1. Product and Service By Value
      2. Reagent Kits
        1. By Value
      3. Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Diagnostics
        1. By Value
      3. Prognostics
        1. By Value
      4. Risk assessment 
        1. By Value
    5. Brazil
      1. By Product and Service
        1. Introduction
          1. Product and Service By Value
        2. Reagent Kits
          1. By Value
        3. Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Diagnostics
          1. By Value
        3. Prognostics
          1. By Value
        4. Risk assessment 
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Breast Cancer Liquid Biopsy Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Biocept Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. F. Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)
    3. Fluxion Biosciences Inc.
    4. Menarini Group (Menarini Silicon Biosystems Inc.)
    5. Myriad Genetics Inc.
    6. NeoGenomics Laboratories Inc.
    7. Qiagen N.V.
    8. Sysmex Corporation
    9. Thermo Fisher Scientific Inc.
    10. Guardant Health Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Straits Research - Access Portal
  • 📊 Preview Report Scope and Structure – Gain immediate visibility into key topics, market segments, and data frameworks covered.
  • 📥 Evaluate Strategic Insights – Access selected charts, statistics, and analyst-driven commentary derived from the final report deliverables.
Get Free Access


We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.